Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that has been studied extensively for its effects on body composition and visceral adipose tissue. Clinical research has primarily focused on people with HIV-associated lipodystrophy, where tesamorelin has demonstrated reductions in visceral abdominal fat.


Research indicates that tesamorelin stimulates the body's natural growth hormone pathway, which can influence body composition and metabolic markers. A recent 2026 meta-analysis of randomized controlled trials found reductions in visceral adipose tissue, trunk fat, hepatic fat, and waist circumference, while lean body mass increased in the studied population.


Because tesamorelin affects the growth hormone and IGF-1 pathways, understanding its safety profile and appropriate clinical context is important. Research has reported potential adverse effects including injection-site reactions, joint or muscle discomfort, and changes in IGF-1 levels.
https://zycarepeptides.com/product/tesamorelin/
https://zycarepeptides.com/ 

Tesamorelin is one of the better-documented peptides in this space — it has actual FDA approval for a specific indication (visceral adiposity in HIV-associated lipodystrophy) and clinical trial data behind it, which distinguishes it from most compounds sold as "research peptides." That said, the approval is narrow, and the effects outside that population are less well established. The safety profile includes effects on IGF-1 levels and glucose metabolism, which is why monitoring matters even in legitimate clinical use. Anyone encountering this via a research-supply website should note that "research use only" labelling is a legal category, not an indication of safety data. There's a discussion on https://chicken-roads1.uk about distinguishing documented compounds from marketed ones — the point about regulatory approval being a narrow signal was well-made. What's your interest in this?